Chicago's Sparx Therapeutics to Build Biologics Manufacturing Facility in China
July 08, 2021 at 04:01 AM EDT
Sparx Therapeutics, a Chicago antibody drug conjugate (ADC) company, will build a 1.2 million square-foot manufacturing facility in Yangzhou , which is west of Shanghai . Sparx uses AI to drive its proprietary target mining platform, identifying cellular targets that offer optimal and synergistic biological activity. The targets are refined by the company's multi-component Sailing™ antibody optimization system and four cutting-edge ADC technologies to improve the success rate. Dr. Gui-Dong Zhu, the CEO of Sparx, has signed a 20-year lease agreement for the facility with Yangzhou Economic Zone. More details.... Share this with colleagues: // //